Key Takeaways
- Revenue up 41% but lithium volatility hit Q4 margins: FY23 revenue reached ₹686 crore, yet gross margin dipped to ~40% in Q4 as peak lithium prices flowed through inventory.
- The MUIS licence is a one-of-a-kind asset: MU Ionic Solutions granted its first-ever external technology licence to Neogen for electrolyte manufacturing, a credential that resets the battery chemicals ambition.
- BuLi Chemicals acquisition closes a strategic loop: Owning n-butyllithium technology lets Neogen offer lithiation reactions in-house, pulling the CSM and advanced intermediate business upstream.
- Guidance embeds a wide lithium-price band: FY24 revenue is guided at ₹800-825 crore on stable lithium, stretching to ₹850-875 crore if prices spike, making the top line partly a commodity call.
- What to watch next quarter: The CAPEX plan and phasing for scaling the electrolyte plant to 30,000 metric tons, promised within two quarters, and any early customer commitments that convert the MUIS licence into contracted revenue.
Battery Chemicals: The MUIS Licence & Electrolyte Roadmap
- MUIS chose Neogen for its first external licence: MU Ionic Solutions, a Mitsubishi Chemical Group company and global leader in electrolytes, had never shared its manufacturing technology outside the group before selecting Neogen.
- The agreement covers both technology and recipes: Neogen gets the manufacturing process plus access to recipes, with royalties payable when a specific recipe is used, combining customer choice with MUIS IP.
- A 1,000-metric-ton electrolyte plant is on track: The Dahej facility is expected to be ready by September 2023, serving as the trial and qualification unit before the larger scale-up.
- The 30,000-metric-ton CAPEX plan is pending: Management committed to sharing the phasing plan within two quarters, after which construction would take 15-18 months, putting the large plant at least two years out.
- Long-term contracts will follow customer readiness: Management expects to enter contracts one by one as customers finalise their plans, with most structured to protect ROEs and ROCs.
- International salt sales are the priority: The company will try to sell electrolyte salts internationally because that represents a bigger market, with the trial facility opening doors to supply companies including MUIS itself.
Dr. Harin Kanani: "MUIS, a global leader in electrolyte manufacturing, has issued its first ever licence to anyone in the world, and they have chosen Neogen Chemicals."
BuLi Chemicals Acquisition: Strategy & Contribution
- The acquisition brings organolithium technology in-house: BuLi Chemicals owns the technology to manufacture n-butyllithium and other organolithium products using lithium metal, completed on 3 May 2023 as a wholly owned subsidiary.
- It unlocks the lithiation reaction for existing customers: The capability lets Neogen offer lithiation to pharma and agrochemical customers, strengthening the CSM and advanced intermediate manufacturing business.
- A significant portion of output is targeted for captive consumption: Management hopes the Dahej unit will consume much of the BuLi production internally, using it as a foundation for future growth in CSM and advanced intermediates.
- FY24 revenue contribution is guided at ₹50-75 crore: The wide range reflects lithium price dependency, with peak potential from current capacity reaching ₹125 crore if prices move favourably.
- International revenues may be lumpy: While domestic pharma demand should be uniform, sales to Japan, Korea and Europe depend on business development activity and could arrive unevenly.
Dr. Harin Kanani: "We also hope that the significant portion of this is consumed in house by our Dahej unit for the lithiation reaction and that will allow us to increase the contribution of either CSM or advanced intermediates and basically be the stepping stone on which or the foundation on which we can plan our future growth."
Margins: Lithium Pass-Through & Gross Margin Reset
- Q4 gross margin fell to ~40% on peak lithium inventory: Lithium prices hit their highest in December-January, and that inventory was consumed by March, compressing the gross margin from the 43-44% run-rate of earlier quarters.
- Management reset gross margin guidance to 42% +/-2%: The historical band was 40% +/-2%, but the shift toward value-added products supports a higher baseline, though management will not guide above this until certainty improves.
- Product mix determines where margins land within the band: Some products carry slightly better gross margins but higher processing costs, so the net effect depends on the mix in any given quarter.
- Bromine price fluctuations are passed through to customers: The company has historically averaged out bromine price movements over the year, passing both benefits and pains to customers, which protects unit margins over a cycle.
- BuLi Chemicals margins swing with lithium prices: The margin profile varies considerably depending on lithium, though management expects to achieve existing EBITDA levels or better, noting lithium metal is even more expensive than lithium carbonate.
Dr. Harin Kanani: "My guidance would be gross margin of 42%, +/-2% that we should look at in the near term, till we have certainty on gross margins better than that. We will let you know."
Organic Business: Capacity, Demand & Competitive Pressure
- Organic chemical revenue grew 28%, driven by volume: Inorganic revenue grew 90%, largely from lithium price increases and new customers, creating a split where volume growth sits in organics and price effects in inorganics.
- Reactor capacity is expanding on schedule: 31 m³ was added in Q3 and Q4 FY23, with another 29 m³ due by September 2023, taking peak quarterly organic revenue potential to ₹175-180 crore, reachable sometime in FY25.
- Demand weakness and Chinese competition are rising in organics: Management manages this by maintaining visibility across a large number of businesses, moving between products, and keeping a pipeline of new products.
- Flavour and fragrance is an emerging growth vector: Good traction with trial volumes at 500 kg to 1 ton, and many projects in the CSM and advanced intermediate space, though FY24 contribution will remain small relative to the growing top line.
- 82 new customers added in FY23, contributing 7% of revenue: The total customer tally now stands at approximately 1,550, with new applications in ceramics, specialty water treatment, and vapour absorption industries adding breadth.
- Bromine market weakness is a headwind: The worldwide flame-retardant market has weakened, especially in China, with high inventories and low demand causing bromine prices to correct significantly after capacity increases by ICL and Albemarle.
Lithium Price Dynamics & Competitive Positioning
- Lithium prices peaked in December, corrected into April, then recovered: Management attributes the correction to a collective inventory correction by China designed to put pressure on lithium miners, with near-term prices expected to move up over the next two years.
- The next two years are expected to remain volatile: After that, a long-term new lithium average price should emerge as supply and demand rebalance, but the transition period will keep input costs unpredictable.
- Neogen expects to be ~10% costlier than Chinese competitors at comparable volumes: The strategy banks on customer interest in de-risking from Chinese sources to offset the premium, with process improvement or quality comfort potentially closing the gap further.
- Lithium raw material prices have cooled post-Q4: The impact of this cooling is already visible in the current year, providing some relief on the input cost side after the Q4 squeeze.
Dr. Harin Kanani: "We should be somewhere around 10% or so costlier in worst-case scenario as compared to the Chinese at a comparable volumes and level. We are basically banking on that and we are also hoping that there is enough interest for a non-chinese source from a de-risking point of view to offset this 10% higher cost."
Balance Sheet & Working Capital
- Working capital deteriorated as capacity and product mix shifted: Inventory rose from ~₹189 crore in March 2022 to ₹282 crore by September 2022, while H1 revenue was ~₹300 crore; in H2, revenue increased to ~₹400 crore but inventory remained stable, suggesting the build is largely complete.
- The target is to return to ~120 days of inventory on net sales by FY24: This would match FY21 levels and release cash as capacity utilisation rises and the product mix stabilises.
- Higher finance costs reflect ongoing expansion: Interest rates rose and the company carried debt for capacity additions, while depreciation increased on incremental reactors that have not yet reached full utilisation.
- The tax rate should improve from ~29% toward 20-22%: The elevated FY23 rate stemmed from Dahej CAPEX creating additional depreciation without significant profit at the tax level; as Dahej reaches full utilisation and CAPEX moderates, the rate is expected to start at 22-25% and then decline over two years.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Organic reactor capacity | Additional 29 m³ to be added | By September 2023 |
| Electrolyte salt & additives capacity | 400 MTPA new capacity commissioned | June or July 2023 |
| 1,000 MT electrolyte plant | Ready at Dahej | By September 2023 |
| FY24 revenue (stable lithium) | ₹800-825 crore (base ~₹750 crore + BuLi ₹50-75 crore) | FY24 |
| FY24 revenue (elevated lithium) | ₹850-875 crore | FY24 |
| FY24 EBITDA growth | 25-30% over FY23 EBITDA | FY24 |
| FY25 revenue | ₹900-1,050 crore, depending on lithium prices | FY25 |
| Gross margin | 42% +/-2% | Near term, until certainty improves |
| Inventory days | ~120 days on net sales | By FY24 |
| Tax rate | Start at 22-25%, move to 20-22% | Over next two financial years |
| Electrolyte CAPEX plan for 30,000 MT | Phasing plan to be shared | Within two quarters |
| Electrolyte plant construction (post-CAPEX clarity) | 15-18 months to build and commission | Starting after CAPEX plan finalised |
| Peak organic revenue | ₹175-180 crore per quarter | Sometime in FY25 |
Key Metrics
| Metric | Q4 FY23 |
|---|---|
| Revenue | ₹203.9 cr, +30% YoY |
| Organic chemicals revenue | ₹138 cr, +39% YoY |
| Inorganic chemicals revenue | ₹66 cr, +14% YoY |
| Domestic / export mix | 55% / 45% |
| EBITDA | ₹32.6 cr, +22% YoY |
| PAT | ₹14.3 cr |
| Gross margin | ~40%, down from 43–44% in Q1–Q3 FY23, driven by peak lithium prices in Dec–Jan inventory |
| FY24 revenue guidance | ₹800–825 cr on stable lithium prices, including BuLi Chem; ₹850–875 cr if lithium prices move up significantly |
| FY24 EBITDA growth guidance | 25–30% increase over FY23 EBITDA |
| FY25 revenue guidance | ₹900–1,050 cr, depending on lithium prices, based on committed CAPEX for regular business and BuLi Chem |
| Net debt | ₹265 cr (including current maturities of long-term debt) |
| New customers added in FY23 | 82, contributing 7% to revenue |
| Total customer count | ~1,550 |
| Products in portfolio | 245; 25 new products in R&D with future demand potential of ~₹2,000 cr |
| Electrolyte plant capacity timeline | 1,000 MT at Dahej expected ready by September 2023 |
| Specialty electrolyte salt capacity timeline | 400 MTPA to be commissioned by June or July 2023 |